Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2022* -- Results Q4 2021 -- -0.73 --
11/03/2021 -- Results Q3 2021 -0.94 2.13 -144.2%
08/05/2021 -- Results Q2 2021 -1.03 -0.86 -19.54%
05/04/2021 -- Results Q1 2021 -0.84 -0.81 -3.77%
03/01/2021 -- Results Q4 2020 -0.99 -0.73 -35.83%
11/05/2020 -- Results Q3 2020 -0.79 -0.66 -19.75%
08/04/2020 -- Results Q2 2020 -0.65 -0.59 -10.96%
04/28/2020 -- Results Q1 2020 -0.56 -0.59 5.08%
*Estimated Date/Time

Earnings

Next Report Date 03/01/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2021
Beat/Miss Upgrade
Return Since -27.84%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.
URL http://www.arvinas.com
Investor Relations URL https://ir.arvinas.com/
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
219.8%
106.7%
-3.29%
-18.03%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-5.89%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.52%
66.74%
-8.47%
-45.16%
-72.91%
-24.16%
-41.68%
-43.75%
19.43%
-22.95%
-11.65%
-49.77%
-12.58%
23.10%
35.12%
389.4%
-3.78%
21.81%
-16.61%
122.5%
-84.97%
214.2%
-25.12%
6.35%
26.35%
15.04%
-25.61%
As of January 20, 2022.

Profile

Edit
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.
URL http://www.arvinas.com
Investor Relations URL https://ir.arvinas.com/
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2022
Last Earnings Release Nov. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FPLRFX 262160.0 USD 2.62%
XPH 5.212M USD 2.52%
F0000172U5 194.00 USD 1.94%
PILL 394637.0 USD 1.80%
FBIOX 110.14M USD 1.58%
FIJYX 24.04M USD 1.02%
PHPSX 66667.00 USD 1.00%
IHE 3.548M USD 0.92%
BBC 167921.0 USD 0.70%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits ARVN Tweets